DoMore Diagnostics is a software company specializing in cancer diagnostics using artificial intelligence. The company has developed methods to improve the prognostic value of tissue biopsies from cancer patients. Through fully automated histotyping, DoMore Diagnostics offers objective and precise prognostic information, which can be decisive for the choice of treatment.
The company's focus is on personalized cancer treatment, with the aim of optimizing patient treatment and streamlining drug development. DoMore Diagnostics has a solid scientific basis for its methods, which underpins its approach to cancer diagnostics. In addition, the company has received EIC Accelerator funding, which is recognition of their innovation and development in the field.